Podcast: Advancing Parkinson’s Disease Care While Maintaining Focus on Dyskinesia

A recent MEDCast presentation explores advancements in Parkinson’s disease (PD) treatment, with a focus on managing dyskinesia—involuntary movements that often develop with long-term levodopa use. Key Insights: Why Dyskinesia Develops: Experts Dr. Kremens and Dr. Hauser discuss the factors leading to dyskinesia, particularly after extended levodopa therapy. New Treatment Approvals: Several new medications, including foscarbidopa/foslevodopa (2024), apomorphine (2025), and extended-release levodopa/carbidopa (2024), offer improved symptom control and may impact dyskinesia development. Managing Dyskinesia Risk: The discussion highlights how these new treatments could influence dyskinesia rates and emphasizes early patient-provider conversations about symptom management. Treatment Strategies: Options for dyskinesia include amantadine delayed-release/extended-release capsules, with recommendations for adjusting treatment based on symptom severity. Surgical & Adjunct Therapies: The panel examines when to consider additional therapies or surgical interventions, stressing the need for individualized care. Clinical Recommendations: Experts encourage proactive discussions in 2025, ensuring patients receive timely, personalized treatment adjustments. The session underscores the importance of staying informed about new PD treatments and prioritizing patient-centered care in managing dyskinesia.